Incidence of second primary malignancies in metastatic castration-resistant prostate cancer: results from observational studies in three countries

  1. Vassilev, Zdravko P.
  2. Soriano Gabarró, Montse
  3. Kaye, James A.
  4. Saltus, Catherine W.
  5. Riedel, Oliver ORCID logo
  6. Scholle, Oliver ORCID logo
  7. Mehtälä, Juha
  8. Korhonen, Pasi
  9. Garbe, Edeltraut
  10. Zong, Jihong

Download
Zdravko-et-al_2020_Incidence of second primary malignancies.pdf 1,41MB
WeightNameValue
1000 Titel
  • Incidence of second primary malignancies in metastatic castration-resistant prostate cancer: results from observational studies in three countries
1000 Autor/in
  1. Vassilev, Zdravko P. |
  2. Soriano Gabarró, Montse |
  3. Kaye, James A. |
  4. Saltus, Catherine W. |
  5. Riedel, Oliver |
  6. Scholle, Oliver |
  7. Mehtälä, Juha |
  8. Korhonen, Pasi |
  9. Garbe, Edeltraut |
  10. Zong, Jihong |
1000 Erscheinungsjahr 2020
1000 LeibnizOpen
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2020-06-09
1000 Erschienen in
1000 Quellenangabe
  • 16(25):1889-1901
1000 FRL-Sammlung
1000 Copyrightjahr
  • 2020
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.2217/fon-2020-0315 |
1000 Ergänzendes Material
  • https://www.futuremedicine.com/doi/suppl/10.2217/fon-2020-0315 |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • AIM: This reports some of the first incidence rate (IR) estimates of second primary malignancies (SPMs) in men with metastatic castration-resistant prostate cancer (mCRPC) in three countries. PATIENTS & METHODS: Claims data from the German Pharmacoepidemiological Research Database; registry data from the Prostate Cancer Data Base Sweden; and combined registry-claims data from the US Surveillance, Epidemiology and End Results-Medicare database were analyzed to obtain overall survival and incidence of SPMs in men with mCRPC. RESULTS: SPMs occurred in 308 German (n = 2360), 273 Swedish (n = 2849) and 172 US (n = 2234) men with mCRPC. IRs of SPMs were 79.0 (95% CI: 70.4–88.4), 101.7 (95% CI: 90.3–114.5) and 59 (95% CI: 50–68) per 1000 person-years in German, Swedish and US cohorts, respectively. CONCLUSION: These studies report some of the first IR estimates of SPMs in men with mCRPC, providing a historical risk estimate of SPM in this patient population.
1000 Sacherschließung
lokal Risk estimate
lokal Second primary malignancies
lokal Healthcare data
lokal Prognosis
lokal Prostate cancer
1000 Fächerklassifikation (DDC)
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/VmFzc2lsZXYsIFpkcmF2a28gUC4=|https://frl.publisso.de/adhoc/uri/U29yaWFubyBHYWJhcnLDsywgTW9udHNl|https://frl.publisso.de/adhoc/uri/S2F5ZSwgSmFtZXMgQS4=|https://frl.publisso.de/adhoc/uri/U2FsdHVzLCBDYXRoZXJpbmUgVy4=|https://orcid.org/0000-0002-1721-502X|https://orcid.org/0000-0002-2633-6587|https://frl.publisso.de/adhoc/uri/TWVodMOkbMOkLCBKdWhh|https://frl.publisso.de/adhoc/uri/S29yaG9uZW4sIFBhc2k=|https://frl.publisso.de/adhoc/uri/R2FyYmUsIEVkZWx0cmF1dA==|https://frl.publisso.de/adhoc/uri/Wm9uZywgSmlob25n
1000 Label
1000 Förderer
  1. Bayer |
1000 Fördernummer
  1. -
1000 Förderprogramm
  1. -
1000 Dateien
1000 Förderung
  1. 1000 joinedFunding-child
    1000 Förderer Bayer |
    1000 Förderprogramm -
    1000 Fördernummer -
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6423539.rdf
1000 Erstellt am 2020-10-15T12:41:55.988+0200
1000 Erstellt von 266
1000 beschreibt frl:6423539
1000 Bearbeitet von 218
1000 Zuletzt bearbeitet 2022-05-13T18:27:58.344+0200
1000 Objekt bearb. Fri May 13 18:27:58 CEST 2022
1000 Vgl. frl:6423539
1000 Oai Id
  1. oai:frl.publisso.de:frl:6423539 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source